Related Experiment Videos

[Relationship between drug resistance and oncogenes in lung cancer cell lines]

Y Tanio1

  • 1Department of Medicine III, Osaka University Medical School.

Nihon Kyobu Shikkan Gakkai Zasshi
|December 1, 1992
PubMed

Insights

Lung cancer patients in Japan have a poor 5-year survival rate, partly due to drug resistance. This study suggests the L-myc oncogene may drive the shift from drug-sensitive to drug-resistant small cell lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Context:

  • Lung cancer poses a significant health challenge, with a low 5-year survival rate in Japan.
  • Drug resistance is a major factor contributing to poor prognosis in lung cancer patients.
  • Oncogenes like ras, myc, and fos are implicated in the development of drug resistance.

Purpose:

  • To investigate the role of the L-myc oncogene in the development of drug resistance in small cell lung cancer.
  • To explore the potential involvement of myc family oncogenes in DNA synthesis and repair processes related to drug resistance.

Summary:

  • This research focuses on a small cell lung cancer cell line, examining the transition from a drug-sensitive to a drug-resistant state.
  • The study identifies the L-myc oncogene as a potential key player in mediating this phenotypic switch.
  • The myc protein's function as a transcription factor suggests a mechanism involving DNA processes in drug resistance.

Impact:

  • Findings may elucidate mechanisms of drug resistance in small cell lung cancer.
  • Identifying the role of L-myc could lead to novel therapeutic strategies targeting drug resistance.
  • This research contributes to understanding the genetic underpinnings of cancer treatment failure.

Related Concept Videos